Peripheral CB1R inhibition modulates food intake and metabolic efficiency in obesity independently of the gut-brain vagal axis
Obesity arises from profound disruptions in neuroendocrine communication and impaired central regulation of energy homeostasis. The endocannabinoid system (ECS), through cannabinoid type-1 receptors (CB1Rs), is a key modulator of feeding, metabolism, and gut-brain signaling. While global CB1R blockade improves metabolic control, its clinical translation has been limited by adverse neuropsychiatric effects, underscoring the therapeutic potential […]
UBS Outlines Three Reasons For Sober Revolution Crushing Spirits Market
UBS Outlines Three Reasons For Sober Revolution Crushing Spirits Market There are just thirteen days until Christmas. Friends and family are gathering; eggnog, spiked with bourbon, dark or spiced rum, or cognac, is flowing, and Christmas music fills homes, restaurants, and bars, blaring from speakers tuned to holiday playlists. But this Christmas season, like the […]
New Weight-Loss Pills Could Arrive Sooner Than We Think
Yevgen_Rychko / Getty Images Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic, Mounjaro, and Wegovy. Still, many others are holding out for GLP-1 medication to arrive in pill form—and they may not have to wait much longer. Orforglipron, a GLP-1 agonist administered as a pill, is […]
Ozempic explained: How this hormone-based drug actually works
Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural gut hormone, providing a new approach for managing type 2 diabetes and obesity. By enhancing insulin production and lowering glucagon levels, it assists in stabilizing blood sugar. Plus, it helps you feel satisfied longer by slowing down digestion […]
Eli Lilly’s Next-Generation Obesity Drug Secures First Phase III Win
Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoints. This study, called TRIUMPH-4, evaluated two doses (9 mg and 12 mg) of the drug for 68 weeks against placebo in adults with obesity […]
Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss market
Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market. Leveraging its established dominance in diabetes care and insulin leadership, the company seeks to accelerate adoption of its GLP-1 therapy, positioning it against rivals like Eli Lilly.
Doctors call for cigarette-style warning label on GLP-1 drugs like Ozempic due to this ‘very dangerous’ risk
“Both restriction and purging behaviors are reinforced by GLP-1s.”
NutraCast: The emotional toll of GLP-1 meds
New research from Chemi Nutra highlights how GLP-1 users want to maintain the benefits of the medication while feeling like their former selves, revealing a significant gap in addressing the broader physiological and psychological impacts of weight loss meds.
Can Non-Diabetics Take Ozempic For Weight Loss? Doctor Answers
Ozempic is the brand name for a medication called semaglutide, which is primarily used to manage type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists
Semaglutide Lowers SGA-Related Cardiometabolic Risk
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk in individuals with schizophrenia spectrum disorders compared with placebo. Medscape Medical News